$1T
Total marketcap
$89.01B
Total volume
37.97%
BTC dominance

AstraZeneca PLC AZNCF Stock

111.25 USD {{ price }} 3.874885% {{change_pct}}%
Exchange
Other OTC
Market Cap
173.19B USD
LOW - HIGH [24H]
109.55 - 111.25 USD
VOLUME [24H]
2.97K USD
{{ volume }}
P/E Ratio
0
Earnings per share
-0.72 USD

AstraZeneca PLC Price Chart

AstraZeneca PLC AZNCF Financial and Trading Overview

AstraZeneca PLC stock price 111.25 USD
Previous Close 107.1 USD
Open 109.55 USD
Bid 0 USD x 0
Ask 0 USD x 0
Day's Range 109.55 - 111.25 USD
52 Week Range 104.5 - 143.9 USD
Volume 2.97K USD
Avg. Volume 2.31K USD
Market Cap 173.19B USD
Beta (5Y Monthly) 0.129406
PE Ratio (TTM) N/A
EPS (TTM) -0.72 USD
Forward Dividend & Yield 2.8 (2.57%)
Ex-Dividend Date August 11, 2022
1y Target Est N/A

AZNCF Valuation Measures

Enterprise Value 198.85B USD
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 3.93278
Price/Book (mrq) 4.795879
Enterprise Value/Revenue 4.515
Enterprise Value/EBITDA 15.88

Trading Information

AstraZeneca PLC Stock Price History

Beta (5Y Monthly) 0.129406
52-Week Change -8.057%
S&P500 52-Week Change -15.35%
52 Week High 143.9 USD
52 Week Low 104.5 USD
50-Day Moving Average 123.05 USD
200-Day Moving Average 123.91 USD

AZNCF Share Statistics

Avg. Volume (3 month) 2.31K USD
Avg. Daily Volume (10-Days) 4.53K USD
Shares Outstanding 1.55B
Float 1.54B
Short Ratio N/A
% Held by Insiders 0.20%
% Held by Institutions 49.25%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 2.9
Trailing Annual Dividend Yield 2.70%
5 Year Average Dividend Yield 304.00%
Payout Ratio N/A
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2021
Most Recent Quarter (mrq) June 30, 2022
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin -2.84%
Operating Margin (ttm) 17.07%
Gross Margin 77.60%
EBITDA Margin 28.43%

Management Effectiveness

Return on Assets (ttm) 5.52%
Return on Equity (ttm) -4.83%

Income Statement

Revenue (ttm) 44.04B USD
Revenue Per Share (ttm) 28.67 USD
Quarterly Revenue Growth (yoy) 31.00%
Gross Profit (ttm) 27.61B USD
EBITDA 12.52B USD
Net Income Avi to Common (ttm) -1252999936 USD
Diluted EPS (ttm) -0.72
Quarterly Earnings Growth (yoy) -34.50%

Balance Sheet

Total Cash (mrq) 4.89B USD
Total Cash Per Share (mrq) 3.16 USD
Total Debt (mrq) 31.39B USD
Total Debt/Equity (mrq) 87.31 USD
Current Ratio (mrq) 0.959
Book Value Per Share (mrq) 23.197

Cash Flow Statement

Operating Cash Flow (ttm) 7.62B USD
Levered Free Cash Flow (ttm) 3.99B USD

Profile of AstraZeneca PLC

Country United Kingdom
State N/A
City Cambridge
Address 1 Francis Crick Avenue
ZIP CB2 0AA
Phone 44 20 3749 5000
Website https://www.astrazeneca.com
Industry Drug Manufacturers—General
Sector(s) Healthcare
Full Time Employees 83100

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Q&A For AstraZeneca PLC Stock

What is a current AZNCF stock price?

AstraZeneca PLC AZNCF stock price today per share is 111.25 USD.

How to purchase AstraZeneca PLC stock?

You can buy AZNCF shares on the Other OTC exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for AstraZeneca PLC?

The stock symbol or ticker of AstraZeneca PLC is AZNCF.

Which industry does the AstraZeneca PLC company belong to?

The AstraZeneca PLC industry is Drug Manufacturers—General.

How many shares does AstraZeneca PLC have in circulation?

The max supply of AstraZeneca PLC shares is 1.56B.

What is AstraZeneca PLC Price to Earnings Ratio (PE Ratio)?

AstraZeneca PLC PE Ratio is now.

What was AstraZeneca PLC earnings per share over the trailing 12 months (TTM)?

AstraZeneca PLC EPS is -0.72 USD over the trailing 12 months.

Which sector does the AstraZeneca PLC company belong to?

The AstraZeneca PLC sector is Healthcare.